Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on the advancement in precision medicine within dermatology and what role genetics, research, and immunology can have for care management going forward.
Precision medicine is advancing quicker than ever before in dermatology, and this is of utmost importance for certain complex dermatologic conditions that have proven difficult to understand and manage, said Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento.
Transcript
What are your thoughts on the future of therapeutic innovation in dermatology?
I'm just excited about all of the therapies that are coming into dermatology. I think it's a very exciting time, where precision medicine is really starting to happen. We're talking about personalized therapies for certain types of diseases. And I think the immunology is really catching up to what we have in the clinic. And that's been in part due to huge research advances and technological advances where what we couldn't do 5 years ago, even a couple of years ago, we're starting to do today. So, it's a really exciting time.
We're advancing medicine quicker than we have in the past where research was primarily performed or done in silos. Small groups, studying things in their lab with groups of 8 to 20 people, but now we're in big medicine where large companies and organizations are looking at big data. They're coupling with machine learning and artificial intelligence.
So, I think we can start to tackle some of these really complex medical dermatologic conditions, and really start to tease out subtleties that we couldn't look at or understand what we were looking at with a small microscope, but now we've got the power to start to tease out how do the genetics really play a role with environment, etc. So, I just think this is the beginning of medicines that are going to be really targeted and highly effective, and it's just an exciting time to be in medical dermatology right now.
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More